Fragile X Syndrome clinical trials

Explore recruiting fragile x syndrome clinical trials.

Recruiting fragile x syndrome studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Fragile X Syndrome trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Evaluation of the safety, tolerability, and effectiveness of CTH120 in adult males with Fragile X syndrome

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A study to learn how safe KER-0193 is, the activity of KER-0193 in the body over a period of time, and the effect of KER-0193 to the body in adult healthy people taking single and multiple doses by the mouth that are increased a little at a time

Belgium

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Safety and tolerability of CTH120, first-in-human phase I study encompassing three parts: Single and Multiple Ascending doses and potential Food Interaction

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of MRM-3379 in Male Participants with Fragile X Syndrome

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents, and Young Adults with Fragile X Syndrome - RECONNECT

Ireland

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults with Fragile X Syndrome

Ireland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Fragile X Syndrome trials by city

Fragile X Syndrome in Toronto Fragile X Syndrome in Vancouver Fragile X Syndrome in Montreal Fragile X Syndrome in Calgary Fragile X Syndrome in Edmonton Fragile X Syndrome in Ottawa Fragile X Syndrome in Winnipeg Fragile X Syndrome in Quebec City Fragile X Syndrome in Hamilton Fragile X Syndrome in Kitchener Fragile X Syndrome in London Fragile X Syndrome in Halifax Fragile X Syndrome in New York Fragile X Syndrome in Los Angeles Fragile X Syndrome in Chicago Fragile X Syndrome in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease